Study Detail

HORIZON 2

A Randomised, Double-blind, Placebo-controlled, Phase 2/3 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Dose Levels of Ad26.COV2.S Administered as a Two-dose Regimen Followed by a Booster in Healthy Children From Birth to 1

Status: Withdrawn

Type: not available

Funder: Janssen Vaccines & Prevention B.V.

Sponsor: Janssen Vaccines & Prevention B.V.

CI: Prof Saul Faust

IRAS-Number: 295926

CPMS-ID: 48501

Approval Date: not available

Back to listing